Evidence map›Paper›PMID 25971759›Full record

ArticleCanadian family physician Medecin de famille canadien2015

Intranasal sumatriptan for migraine in children.

Ran D Goldman, Garth D Meckler

Abstract read
In one paragraph

Article in Canadian family physician Medecin de famille canadien, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ran D Goldman
Garth D Meckler

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

questionI am seeing more and more children and adolescents with headaches that can be defined as migraine headache. I have read about intranasal sumatriptan as an abortive therapy. Is this an effective treatment? ANSWER: Acute migraine headache among children and adolescents is common and treatment is challenging. Intranasal sumatriptan is a safe and mostly effective option for children and adolescents. Currently the recommended dose is 20 mg for children who weigh more than 40 kg and 10 mg for children who weigh between 20 and 39 kg. Larger trials should be conducted to overcome the limitations of small sample sizes, potential low plasma concentration, and placebo effects witnessed in studies to date.

Indexed as

Administration, IntranasalAdolescentChildHumansMigraine DisordersSerotonin 5-HT1 Receptor AgonistsSumatriptanSerotonin 5-HT1 Receptor AgonistsSumatriptan

Identifiers

PMID25971759
PMCPMC4430059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.